JANUX THERAPEUTICS INC (JANX) Fundamental Analysis & Valuation

NASDAQ:JANX • US47103J1051

Current stock price

13.9 USD
-0.16 (-1.14%)
At close:
13.99 USD
+0.09 (+0.65%)
After Hours:

This JANX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. JANX Profitability Analysis

1.1 Basic Checks

  • In the past year JANX has reported negative net income.
  • In the past year JANX has reported a negative cash flow from operations.
  • JANX had negative earnings in each of the past 5 years.
  • JANX had a negative operating cash flow in each of the past 5 years.
JANX Yearly Net Income VS EBIT VS OCF VS FCFJANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • JANX has a better Return On Assets (-11.34%) than 82.08% of its industry peers.
  • With an excellent Return On Equity value of -11.88%, JANX belongs to the best of the industry, outperforming 85.55% of the companies in the same industry.
Industry RankSector Rank
ROA -11.34%
ROE -11.88%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JANX Yearly ROA, ROE, ROICJANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for JANX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JANX Yearly Profit, Operating, Gross MarginsJANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. JANX Health Analysis

2.1 Basic Checks

  • JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JANX Yearly Shares OutstandingJANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
JANX Yearly Total Debt VS Total AssetsJANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 11.61 indicates that JANX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 11.61, JANX belongs to the best of the industry, outperforming 83.43% of the companies in the same industry.
  • There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.61
ROIC/WACCN/A
WACC9.28%
JANX Yearly LT Debt VS Equity VS FCFJANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 39.04 indicates that JANX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 39.04, JANX belongs to the best of the industry, outperforming 98.65% of the companies in the same industry.
  • JANX has a Quick Ratio of 39.04. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
  • JANX's Quick ratio of 39.04 is amongst the best of the industry. JANX outperforms 98.65% of its industry peers.
Industry RankSector Rank
Current Ratio 39.04
Quick Ratio 39.04
JANX Yearly Current Assets VS Current LiabilitesJANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. JANX Growth Analysis

3.1 Past

  • The earnings per share for JANX have decreased strongly by -42.97% in the last year.
  • Looking at the last year, JANX shows a decrease in Revenue. The Revenue has decreased by -5.55% in the last year.
  • The Revenue has been growing slightly by 5.12% on average over the past years.
EPS 1Y (TTM)-42.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.67%
Revenue 1Y (TTM)-5.55%
Revenue growth 3Y5.12%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.47% on average over the next years.
  • Based on estimates for the next years, JANX will show a very strong growth in Revenue. The Revenue will grow by 90.74% on average per year.
EPS Next Y-50.24%
EPS Next 2Y-34.91%
EPS Next 3Y-29.76%
EPS Next 5Y-4.47%
Revenue Next Year-52.07%
Revenue Next 2Y-31.5%
Revenue Next 3Y18.65%
Revenue Next 5Y90.74%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

0

4. JANX Valuation Analysis

4.1 Price/Earnings Ratio

  • JANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year JANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JANX Price Earnings VS Forward Price EarningsJANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JANX Per share dataJANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • JANX's earnings are expected to decrease with -29.76% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.91%
EPS Next 3Y-29.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JANX Dividend Analysis

5.1 Amount

  • JANX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JANX Fundamentals: All Metrics, Ratios and Statistics

JANUX THERAPEUTICS INC

NASDAQ:JANX (3/23/2026, 4:30:42 PM)

After market: 13.99 +0.09 (+0.65%)

13.9

-0.16 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners101.78%
Inst Owner Change-5.04%
Ins Owners1.79%
Ins Owner Change3.64%
Market Cap845.54M
Revenue(TTM)10.00M
Net Income(TTM)-113.63M
Analysts84.62
Price Target61.97 (345.83%)
Short Float %18.31%
Short Ratio7.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.22%
Min EPS beat(2)22.38%
Max EPS beat(2)38.06%
EPS beat(4)3
Avg EPS beat(4)12.61%
Min EPS beat(4)-15.55%
Max EPS beat(4)38.06%
EPS beat(8)6
Avg EPS beat(8)12.16%
EPS beat(12)10
Avg EPS beat(12)18.29%
EPS beat(16)13
Avg EPS beat(16)16.68%
Revenue beat(2)1
Avg Revenue beat(2)67.39%
Min Revenue beat(2)-100%
Max Revenue beat(2)234.78%
Revenue beat(4)1
Avg Revenue beat(4)-16.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)234.78%
Revenue beat(8)3
Avg Revenue beat(8)107.3%
Revenue beat(12)7
Avg Revenue beat(12)124.48%
Revenue beat(16)11
Avg Revenue beat(16)134.38%
PT rev (1m)0%
PT rev (3m)-8.99%
EPS NQ rev (1m)13.92%
EPS NQ rev (3m)13.92%
EPS NY rev (1m)7.28%
EPS NY rev (3m)7.37%
Revenue NQ rev (1m)142.21%
Revenue NQ rev (3m)142.21%
Revenue NY rev (1m)242.96%
Revenue NY rev (3m)242.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 84.55
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-2.75
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS0.16
BVpS15.73
TBVpS15.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.34%
ROE -11.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.4%
Cap/Sales 10.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 39.04
Quick Ratio 39.04
Altman-Z 11.61
F-Score3
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)54.49%
Cap/Depr(5y)455.36%
Cap/Sales(3y)12.24%
Cap/Sales(5y)30.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.67%
EPS Next Y-50.24%
EPS Next 2Y-34.91%
EPS Next 3Y-29.76%
EPS Next 5Y-4.47%
Revenue 1Y (TTM)-5.55%
Revenue growth 3Y5.12%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-52.07%
Revenue Next 2Y-31.5%
Revenue Next 3Y18.65%
Revenue Next 5Y90.74%
EBIT growth 1Y-59.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.11%
EBIT Next 3Y-19.03%
EBIT Next 5Y-2.71%
FCF growth 1Y-88.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.69%
OCF growth 3YN/A
OCF growth 5YN/A

JANUX THERAPEUTICS INC / JANX Fundamental Analysis FAQ

What is the fundamental rating for JANX stock?

ChartMill assigns a fundamental rating of 4 / 10 to JANX.


What is the valuation status for JANX stock?

ChartMill assigns a valuation rating of 0 / 10 to JANUX THERAPEUTICS INC (JANX). This can be considered as Overvalued.


Can you provide the profitability details for JANUX THERAPEUTICS INC?

JANUX THERAPEUTICS INC (JANX) has a profitability rating of 2 / 10.